Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
AMD: China Restart Sparks Clear AI Demand Signal - Tactical Long Trade
Q3 strength, cash flow resilience, and a China reopening narrative give AMD a compelling short-to-mid term trade setup.
AMD reported accelerating revenue and margin improvement in Q3 FY2025, producing strong operating cash flow and net income. Recent market commentary a...
Third Time’s the Charm? Event Trade on Outlook Therapeutics as Lytenava Eyes U.S. Pathway
Small-cap, high-volatility play tied to regulatory momentum — buy a targeted swing with tight sizing and a hard stop.
Outlook Therapeutics (OTLK) is an event-driven microcap that just cleared major regulatory hurdles in Europe and has been recapitalizing ahead of a li...
AMD's Two 'Masked' Advantages — Why a Pullback Is a Tradeable Long
Hidden technical breadth and a balance-sheet buffer make AMD a high-conviction trade for AI cycle exposure
AMD has quietly turned the corner: accelerating revenue, improving margins and an emerging AI GPU capability give the company two under-appreciated ad...
Brookfield Wealth Engine: Misunderstood Upside at ~3.3% Yield
BAM's scale and cash-generation are underappreciated - actionable long trade with entry, stops and targets
Brookfield Asset Management runs one of the world’s largest alternative-asset platforms (USD 1.151 trillion AUM) and is showing back-to-back quarter...
Viking Therapeutics: Swing Long Off Cash-Rich Balance Sheet, But Trial Competition and Dilution Are Real
Entry at the low-$30s, tight stop; catalysts and cash runway support a short-term swing — keep position size disciplined.
Viking Therapeutics (VKTX) is trading in the mid-$30s after a steady increase in R&D spend and accelerating net losses. The company sits with several ...
AST SpaceMobile: Speculative Buy — Betting on Execution as BlueBird 6 Validates Scale
Balance-sheet strength and recent operational milestones justify a high-risk entry; keep position size small.
AST SpaceMobile has moved from promise to execution. Recent financing and operational activity — including BlueBird 6 testing — give investors a p...
Mineralys (MLYS) - Pre-NDA Momentum, Pivotal 2026 Optionality; Tactical Long with a High-Risk Payoff
Lorundrostat data and fresh financing create a multi-quarter runway into regulatory readouts — trade idea for a position-sized long.
Mineralys has taken lorundrostat through pivotal testing in uncontrolled and resistant hypertension, published late-breaking data across 2025, and rei...
Nike: Buy the Turnaround — A Defined-Entry Trade as Fundamentals Rebound
Company-level improvements meet a beaten-down multiple; trade with a plan.
Nike has been through a multi-year valuation reset. Recent quarterly results and an earnings beat (12/18/2025) suggest demand stabilization while the ...
Broadcom Upgrade: Earnings Revisions and AI Tailwinds Make a Strong Buy
Sequential revenue acceleration and hefty cash flow justify an aggressive upgrade to Strong Buy with defined entries, stops and targets.
Broadcom's latest fiscal 2025 results show accelerating revenue (Q1-Q4 progression to $18.015B), strong operating cash flow and rising dividends. Give...
Dutch Bros (BROS) - A Coffee Growth Story Worth Owning: actionable long with defined risk bands
Strong unit economics, steady cash flow and a franchising mix make BROS my favorite non-tech growth pick right now
Dutch Bros is translating rapid unit growth into reliable cash flow while keeping leverage modest. Recent quarters show improving operating margins an...
Nexa Resources: Asset Sales, Smelter-Levered Margins and a Momentum Breakout — Tactical Buy
Portfolio pruning and improving market technicals create a favorable risk/reward for a swing trade into NEXA
Nexa Resources looks buyable after the market rewarded portfolio optimization moves and shares broke higher on heavy volume. The company's smelting-he...
Novartis: A Quiet Hedge Amid Market Crowding — Buy the Relative Safety
Diversified pharma with a rising dividend and policy noise priced in — tactical long with defined stops and targets.
Novartis (NVS) trades near $139 and offers a ~2.9% cash yield, steady dividend growth and broad pipeline exposure (oncology, rare disease, ophthalmolo...